EMA Deals with Manufacturing Deficiencies for Cancer Medicine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Deals with Manufacturing Deficiencies for Cancer Medicine


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has recommended that the anticancer medicine DepoCyte be recalled from EU countries following the discovery of manufacturing deficiencies at Pacira Pharmaceuticals’ San Diego site. The deficiencies identified relate to adequate sterility assurance in the manufacturing process of DepoCyte. Production and batch release of the medicine are currently on hold, and new batches will only be manufactured once the deficiencies have been resolved and GMP compliancy confirmed by a reinspection.

According to a press release from EMA, there has been no evidence of any microbial contamination of DepoCyte on the market. The recall is being implemented as a precautionary measure in countries where suitable alternatives are available. For countries without therapeutic alternatives, DepoCyte will remain on the market, but with specific recommendations for monitoring patient safety and any signs of infection.

The inspection was conducted jointly by regulators from France and the UK at the DepoCyte manufacturing site in San Diego in July 2012. The EMA’s Committee for Medicinal Products for Human Use (CHMP) believes that the lack of sterility assurance poses a theoretical risk of sterility failure. Current data, however, have not suggested that there has been any Negative impact on the finished product.

DepoCyte is a prolonged release liposomal suspension for injection containing cytarabine for the intrathecal treatment of lymphomatous meningitis. The medicine was authorized in the EU in July 2001.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here